Author:
Kucharz Jakub,Budnik Monika,Dumnicka Paulina,Pastuszczak Maciej,Kuśnierz-Cabala Beata,Demkow Tomasz,Popko Katarzyna,Wiechno Pawel
Publisher
Springer International Publishing
Reference23 articles.
1. American Urological Association (2018) Clear cell renal cell carcinoma: Fuhrman nuclear grade.
https://www.auanet.org/education/auauniversity/education-products-and-resources/pathology-for-urologists/kidney/renal-cell-carcinomas/clear-cell-renal-cell-carcinoma-fuhrman-nuclear-grade
. Accessed on 30 Nov 2018
2. Bono P, Rautiola J, Utriainen T, Joensuu H (2011) Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta Oncol 50:569–573
3. Buda–Nowak A, Kucharz J, Dumnicka P, Kuzniewski M, Herman RM, Zygulska AL, Kusnierz–Cabala B (2017) Sunitinib–induced hypothyroidism predicts progression–free survival in metastatic renal cell carcinoma patients. Med Oncol 34(4):68
4. Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884–896
5. Chu D, Lacouture ME, Fillos T, Wu S (2008) Risk of hand–foot skin reaction with sorafenib: a systematic review and meta–analysis. Acta Oncol 47(2):176–186